Medpace Holdings (MEDP) Amortization of Deferred Charges (2015 - 2019)
Medpace Holdings' (MEDP) quarterly Amortization of Deferred Charges came in at $700000.0 in Q3 2019, up 354.55% on a YoY basis from $154000.0 in Q3 2018, and down 4.89% quarter-over-quarter from $736000.0 in Q2 2019.
Analysis
Medpace Holdings (MEDP) Amortization of Deferred Charges (2015 - 2019) Analysis & Trends
Medpace Holdings (MEDP) has reported Amortization of Deferred Charges for 5 consecutive years, with $700000.0 the latest figure, recorded in Q3 2019.
- For the quarter ending Q3 2019, Amortization of Deferred Charges rose 354.55% year-over-year to $700000.0; the trailing twelve-month figure through Jun 2020 stood at $700000.0 (down 40.27% YoY), and the FY2019 full-year result was $954000.0, up 55.12% from the prior year.
- Amortization of Deferred Charges declined to $700000.0 in Q3 2019 per MEDP's latest filing, from $736000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $736000.0 in Q2 2019 and bottomed at $138000.0 in Q1 2019.
- Historically, Amortization of Deferred Charges has averaged $381625.0 across 5 years, with a median of $166500.0 in 2017.
- The sharpest annual moves came in 2017 and 2019: Amortization of Deferred Charges slumped 75.55% in 2017, then surged 365.82% in 2019.
- Over 5 years, Amortization of Deferred Charges stood at $679000.0 in 2015, then declined by 18.7% to $552000.0 in 2016, then tumbled by 70.29% to $164000.0 in 2017, then fell by 12.2% to $144000.0 in 2018, then surged by 386.11% to $700000.0 in 2019.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $700000.0, $736000.0, and $138000.0 for Q3 2019, Q2 2019, and Q1 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 700,000.00 |
| Jun 30, 2019 | 736,000.00 |
| Mar 31, 2019 | 138,000.00 |
| Dec 31, 2018 | 144,000.00 |
| Sep 30, 2018 | 154,000.00 |
| Jun 30, 2018 | 158,000.00 |
| Mar 31, 2018 | 159,000.00 |
| Dec 31, 2017 | 164,000.00 |
| Sep 30, 2017 | 166,000.00 |
| Jun 30, 2017 | 167,000.00 |
| Mar 31, 2017 | 165,000.00 |
| Dec 31, 2016 | 552,000.00 |
| Sep 30, 2016 | 679,000.00 |
| Jun 30, 2016 | 673,000.00 |
| Mar 31, 2016 | 672,000.00 |
| Dec 31, 2015 | 679,000.00 |